FY2025 EPS Estimate for Hims & Hers Health Lifted by Analyst

Hims & Hers Health, Inc. (NYSE:HIMS) – Equities research analysts at Leerink Partnrs raised their FY2025 earnings per share (EPS) estimates for shares of Hims & Hers Health in a research note issued on Tuesday, November 5th. Leerink Partnrs analyst M. Cherny now expects that the company will post earnings of $0.49 per share for the year, up from their prior estimate of $0.39. The consensus estimate for Hims & Hers Health’s current full-year earnings is $0.22 per share.

Hims & Hers Health (NYSE:HIMS) last announced its quarterly earnings results on Monday, November 4th. The company reported $0.32 earnings per share for the quarter, beating the consensus estimate of $0.06 by $0.26. The firm had revenue of $401.56 million for the quarter, compared to analysts’ expectations of $382.20 million. Hims & Hers Health had a return on equity of 10.97% and a net margin of 8.19%. The company’s revenue was up 77.1% on a year-over-year basis. During the same period in the prior year, the business posted ($0.04) earnings per share.

HIMS has been the topic of a number of other research reports. Truist Financial increased their price objective on Hims & Hers Health from $13.00 to $23.00 and gave the stock a “hold” rating in a research report on Thursday, July 18th. Canaccord Genuity Group lifted their price target on Hims & Hers Health from $24.00 to $28.00 and gave the company a “buy” rating in a research report on Tuesday. Deutsche Bank Aktiengesellschaft boosted their price objective on Hims & Hers Health from $23.00 to $27.00 and gave the stock a “hold” rating in a report on Wednesday. Imperial Capital downgraded shares of Hims & Hers Health from an “outperform” rating to an “in-line” rating in a research note on Friday, August 9th. Finally, Needham & Company LLC assumed coverage on shares of Hims & Hers Health in a research note on Thursday, August 22nd. They issued a “buy” rating and a $24.00 price target for the company. Eight research analysts have rated the stock with a hold rating and eight have given a buy rating to the company’s stock. Based on data from MarketBeat.com, Hims & Hers Health currently has an average rating of “Moderate Buy” and a consensus target price of $21.21.

Hims & Hers Health Price Performance

NYSE HIMS opened at $23.42 on Thursday. The company’s 50 day simple moving average is $18.57 and its two-hundred day simple moving average is $18.33. Hims & Hers Health has a 1 year low of $6.58 and a 1 year high of $25.74. The stock has a market capitalization of $5.03 billion, a PE ratio of 53.22 and a beta of 1.06.

Institutional Trading of Hims & Hers Health

A number of institutional investors and hedge funds have recently added to or reduced their stakes in HIMS. Quantbot Technologies LP raised its holdings in Hims & Hers Health by 3,444.9% in the 1st quarter. Quantbot Technologies LP now owns 214,677 shares of the company’s stock worth $3,321,000 after purchasing an additional 208,621 shares in the last quarter. IvyRock Asset Management HK Ltd purchased a new position in shares of Hims & Hers Health during the first quarter valued at about $433,000. Swiss National Bank raised its stake in Hims & Hers Health by 0.7% in the first quarter. Swiss National Bank now owns 281,500 shares of the company’s stock worth $4,355,000 after buying an additional 2,000 shares in the last quarter. Sei Investments Co. lifted its holdings in Hims & Hers Health by 206.9% in the first quarter. Sei Investments Co. now owns 56,202 shares of the company’s stock worth $869,000 after buying an additional 37,890 shares during the period. Finally, Headlands Technologies LLC bought a new stake in Hims & Hers Health during the 1st quarter valued at approximately $228,000. Hedge funds and other institutional investors own 63.52% of the company’s stock.

Insider Activity at Hims & Hers Health

In other Hims & Hers Health news, Director Christiane Pendarvis sold 7,000 shares of the business’s stock in a transaction that occurred on Tuesday, August 27th. The stock was sold at an average price of $15.15, for a total value of $106,050.00. Following the completion of the sale, the director now owns 23,917 shares in the company, valued at approximately $362,342.55. The trade was a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. In other Hims & Hers Health news, CEO Andrew Dudum sold 188,888 shares of the company’s stock in a transaction that occurred on Tuesday, September 3rd. The stock was sold at an average price of $14.56, for a total transaction of $2,750,209.28. Following the completion of the transaction, the chief executive officer now owns 33,502 shares of the company’s stock, valued at $487,789.12. This represents a 0.00 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Also, Director Christiane Pendarvis sold 7,000 shares of the stock in a transaction that occurred on Tuesday, August 27th. The stock was sold at an average price of $15.15, for a total value of $106,050.00. Following the completion of the sale, the director now owns 23,917 shares of the company’s stock, valued at approximately $362,342.55. This trade represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 854,547 shares of company stock worth $15,987,230 in the last ninety days. 17.71% of the stock is owned by company insiders.

Hims & Hers Health Company Profile

Hims & Hers Health, Inc operates a telehealth platform that connects consumers to licensed healthcare professionals in the United States, the United Kingdom, and internationally. The company offers a range of curated prescription and non-prescription health and wellness products and services available to purchase on its websites and mobile application directly by customers.